FDA–SEC Agreement Raises the Stakes For Biotech Investor Disclosures
The U.S. Food and Drug Administration (FDA) and Securities and Exchange Commission (SEC) have signed a first-of-its-kind memorandum of understanding (MOU) that could bring greater scrutiny to how pharmaceutical and biotechnology companies describe clinical results, regulatory interactions and product-development milestones to investors.
The three-year FDA–SEC agreement, signed August 31, establishes formal procedures for exchanging information about FDA-regulated products and companies. Significantly, that exchange may include nonpublic information transmitted through secure channels.
The SEC may use information received from FDA when reviewing public-company filings or conducting enforcement investigations. The agreement specifically identifies potentially false or misleading statements about clinical trial results, FDA review status, product approvals and other regulatory matters that could affect investment decisions.
The agencies have not created new disclosure requirements or enforcement authority. Instead, the agreement gives them a more direct mechanism for comparing what a company tells investors with what it has told or learned from FDA. Law360 reported that the agencies intend to strengthen information sharing for their respective oversight and compliance responsibilities, but the MOU arrangement potentially gives securities regulators greater access to nonpublic FDA information when evaluating whether drugmakers misled investors.
Why clinical-stage companies face particular risk
Early-stage biotechnology companies can be especially sensitive to the new framework. These companies often have little or no product revenue, making their valuations highly dependent on a small number of clinical and regulatory events. A statement about a trial endpoint, safety signal or FDA meeting can therefore produce a substantial change in the company’s stock price or financing prospects.
Potential areas of heightened scrutiny include:
-
FDA feedback: Companies should distinguish carefully between FDA agreeing with a development plan, indicating that a proposal appears reasonable and simply not objecting to it.
-
Clinical results: “Positive” or “encouraging” topline announcements must fairly describe missed endpoints, adverse events, protocol changes, subgroup analyses and other information that could materially alter an investor’s interpretation.
-
Regulatory setbacks: Clinical holds, requests for additional studies, manufacturing deficiencies and negative application-review developments may require prompt evaluation for disclosure.
-
Development timelines: Public projections should remain consistent with FDA correspondence, trial-enrollment realities and the work still required before a marketing application can be filed or approved.
-
Insider trading controls: Material FDA communications and unannounced clinical results should immediately trigger appropriate escalation and trading restrictions.
The risk is not confined to SEC filings. Statements in press releases, investor presentations, earnings calls, conference remarks, websites and social media can all become part of the SEC’s assessment of whether investors received accurate and complete information.
A recent legal analysis from Regulatory Oversight notes that the agreement creates dedicated contacts within the SEC’s Division of Corporation Finance and Division of Enforcement, suggesting that shared information may support both routine disclosure reviews and active investigations.
Practical steps for emerging biotechs
Clinical-stage companies should consider integrating their regulatory, clinical, legal and investor-relations functions more closely. Public statements about FDA interactions should be checked against agency correspondence and official meeting minutes, while disclosures about trial results should be reviewed by personnel who understand the complete dataset, not only the most favorable findings.
Companies should also document decisions about whether regulatory developments are material, establish procedures for escalating FDA communications and ensure that information from clinical sites, contract research organizations and development partners reaches disclosure personnel promptly.
Although the MOU most directly affects public companies, privately held startups should not dismiss it. Federal antifraud protections also apply to private securities offerings, and statements made during venture financings, strategic transactions or preparations for an initial public offering may later be examined against the underlying regulatory record.
The agreement does not mean that every difference in wording will result in an investigation. It does, however, reduce the separation between FDA’s regulatory files and the SEC’s oversight of investor communications. For development-stage companies, precision and internal coordination will become even more important.
As the agencies put this new framework into practice, MichBio will work continue to assess its impact, share practical compliance guidance and ensure that emerging companies can communicate scientific and regulatory progress accurately and effectively.
